The PCR-LMA study aimed to consolidate the PETHEMA nationwide centralized diagnostic and monitoring platform (PLATAFO-LMA), focusing on providing timely molecular diagnoses for adult patients with AML, prioritizing potentially druggable mutations (i.e., NPM1, FLT3, and IDH). This evidence concerns the gene FLT3 and acute myeloid leukemia.